GILD management rumored to be meeting with RBC Capital. If true, anything here that GILD might want? In latest earnings CC, CEO said GILD has always concentrated on volume sales....
and then there is this:
"And as you can see, we've had a very busy quarter. We've announced key changes this quarter that helped to address really all 3 of these priorities. And importantly, we've made these changes against a backdrop of strong financials and really promising pipeline progress.
So let me say a few words about the major steps we've taken to: first of all, strengthen the pipeline with the Galapagos collaboration; secondly, I want to dive a little bit into the highlights from our current pipeline; and three, talk a little bit about the organizational changes as well.
So first, on Galapagos. It's fresh news. Earlier this month, we announced an exciting new collaboration with Galapagos. As you know, Galapagos is a highly productive R&D engine. They have 7 medicines now in clinical development, including filgotinib, which has a very comprehensive of life cycle program. And they have more than 20 medicines now in preclinical and their model has been very productive at producing new candidates for the clinic every year. And of course with our increased investments, we would expect that to even increase in the future.
This is a really unique collaboration because it combines complementary strengths between Gilead and Galapagos and very importantly, and as you know, we structured this to allow Galapagos to remain independent. Many of you know my past, I'm a big believer that innovation requires independence, I think, to be preserved. And the structure of this deal allows us to preserve the great science and talent at Galapagos. They can invest and innovate to accelerate the progress based upon our investments. And in return, we have an exclusive access right to their proven drug discovery platform. All of this, I believe, will help patients, science and our business in a very significant way.
So I was really pleased this was the first collaboration that I could announce under my tenure and yet, this is still a beginning. We'll continue to explore other ways to strengthen our pipeline and our innovation network in the future...".
Secondly, on the pipeline side, this has been an important time for our existing pipeline. Let me touch on a couple of things that speak to our growth potential before handing it over to Johanna. And there's 2 things I want to just highlight here: some recent promising HIV data that we presented recently; and secondly, since the last quarter, our plans to file filgotinib for approval.
